Leuject

Cladribine, the active ingredient in Leuject, is a purine nucleoside analog presented as a subcutaneous injection for use in the treatment of relapsing forms of multiple sclerosis in adults. It works by selectively depleting lymphocytes that contribute to disease activity, offering a disease‑modifying approach for patients with active disease.

GNH USA supplies Leuject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leuject (cladribine) is indicated for disease‑modifying therapy in multiple sclerosis, targeting the immune pathways that drive relapses and progression.

Multiple sclerosis (relapsing‑remitting): reduces annualized relapse rate and slows disability accumulation. Relapsing‑progressive MS with active disease: delays confirmed disability progression. Active MRI lesions in MS: decreases formation of new inflammatory lesions.

Leuject may cause a range of adverse reactions, ranging from mild to serious.

Common Side Effects: - Lymphopenia: reduced lymphocyte counts. - Infections: upper respiratory or urinary tract infections. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Fatigue: generalized tiredness. - Injection site reactions: redness or swelling.

Serious or Rare Side Effects: - Severe lymphopenia leading to opportunistic infections. - Reactivation of latent viruses (e.g., herpes zoster). - Malignancies: rare reports of skin or lymphoid cancers. - Autoimmune hepatitis: liver enzyme elevations. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Progressive multifocal leukoencephalopathy (PML): extremely rare but life‑threatening.

Before initiating Leuject, clinicians should assess baseline immune status and monitor patients throughout therapy.

Monitor lymphocyte counts: perform regular blood tests to detect lymphopenia. Screen for infections: evaluate for active or latent infections before treatment. Avoid live vaccines: do not administer live attenuated vaccines during therapy. Pregnancy and breastfeeding: discuss risks; use only if benefits outweigh potential harms. Assess hepatic function: monitor liver enzymes periodically. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine may interact with other agents that affect immune function or drug metabolism.

Major Interactions (Avoid): - Concurrent immunosuppressants (e.g., azathioprine, cyclophosphamide): may exacerbate lymphocyte depletion. - Live vaccines: increased risk of vaccine‑derived infection. - Strong CYP3A4 inhibitors: may alter cladribine metabolism (theoretical).

Moderate Interactions (Monitor Closely): - Other disease‑modifying therapies for MS (e.g., interferon‑β, glatiramer acetate): monitor additive immunosuppression. - Antiviral prophylaxis agents: adjust dosing if needed. - Antiepileptic drugs that induce hepatic enzymes: may reduce exposure. - Vaccinations with inactivated vaccines: assess immune response. - Herbal supplements affecting immunity (e.g., echinacea): advise caution.